Baseline characteristics of the GRADUATE studies: Phase III randomized, placebo-controlled studies investigating subcutaneous gantenerumab in participants with early Alzheimer’s disease
GRADUATE I and GRADUATE II are two ongoing, identical, global, randomized, double-blind, placebo-controlled, parallel-group, Phase III studies assessing the efficacy and safety of subcutaneous gantenerumab in early (prodromal-to-mild) Alzheimer’s disease. Here, we present the baseline characteristics of the enrolled participants across of the GRADUATE studies.